Clinical Trial Results, Partnerships, and Reimbursement Rates - Research Report on Celldex, Centene, Enanta, Novartis, and BG

   Clinical Trial Results, Partnerships, and Reimbursement Rates - Research
        Report on Celldex, Centene, Enanta, Novartis, and BG Medicine

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, December 13, 2013

NEW YORK, December 13, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Celldex
Therapeutics, Inc. (NASDAQ: CLDX), Centene Corp. (NYSE: CNC), Enanta
Pharmaceuticals, Inc. (NASDAQ: ENTA), Novartis AG (NYSE: NVS), and BG
Medicine, Inc. (NASDAQ: BGMD). Today's readers may access these reports free
of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Celldex Therapeutics, Inc. Research Report

On December 10, 2013, Celldex Therapeutics, Inc. (Celldex) announced positive
results from a preclinical combination study of CDX-301 (FMS-like tyrosine
kinase-3 ligand or Flt3L) and Mozobil (Plerixafor injection, formerly
AMD3100). According to the Company, the study demonstrates that the
combination of these agents significantly increases hematopoietic stem cell
mobilization in mice. The Company also informed that the data support future
clinical development of CDX-301 and demonstrate a novel potent cell
mobilization regimen combining CDX-301 and Mozobil®, which may have
significant potential for use in autologous and allogeneic hematopoietic stem
cell transplantation. "The data presented today further demonstrate the
potential for CDX-301 to improve both autologous and allogeneic hematopoietic
stem cell transplantation and, importantly, show the ability for CDX-301 to
combine effectively with other cell mobilization agents," said Tibor Keler,
PhD, Senior Vice President and Chief Scientific Officer at Celldex. "If what
has been demonstrated in preclinical models can be applied to a clinical
setting, this regimen could improve stem cell transplantation outcomes for
patients across a broad range of indications. We plan to initiate a pilot
clinical study evaluating CDX-301 alone and in combination with Mozobil® in
the transplant setting in early 2014 and look forward to seeing how this
program progresses." The Full Research Report on Celldex Therapeutics, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=DDD

http://www.analystscorner.com/r/full_research_report/b443_CLDX

--

Centene Corp. Research Report

On December 10, 2013, Centene Corp. (Centene) announced that its wholly-owned
behavioral health subsidiary Cenpatico of Arizona is entering into a strategic
alliance with the University of Arizona Health Network, seeking opportunities
to deliver an innovative and highly effective model for whole person
healthcare in Arizona. "Both Centene and UAHN bring together their years of
experience in managing these vulnerable populations, and we look forward to
participating in the state's procurement in 2014, in which we will articulate
the vision for integrated healthcare," said Jason M. Harrold, Executive Vice
President of Specialty Business at Centene. The Full Research Report on
Centene Corp. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/e85d_CNC

--

Enanta Pharmaceuticals, Inc. Research Report

On December 10, 2013, Enanta Pharmaceuticals, Inc. (Enanta) announced results
from the SAPPHIRE-II study, conducted by AbbVie for the treatment of hepatitis
C virus (HCV) genotype 1 (GT1) infection, using a regimen containing the
Company's lead protease inhibitor ABT-450. According to the Company, results
from the SAPPHIRE-II trial demonstrated a sustained virologic response at 12
weeks post-treatment of 96% in chronically infected GT1 HCV treatment
experienced adult patients who had previously failed pegylated interferon and
ribavirin treatment. "The high SVR rates in this SAPPHIRE-II trial and the
previously reported SAPPHIRE-I trial further validate this 3D regimen plus
ribavirin for both treatment-naive and treatment-experienced patients," said
Jay R. Luly, Ph.D., President and CEO of Enanta. "We look forward to the
remaining phase 3 studies reading out using the same 3D regimen with and
without ribavirin, as well as in the treatment of HCV patients with
cirrhosis." The Full Research Report on Enanta Pharmaceuticals, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/a066_ENTA

--

Novartis AG Research Report

On December 6, 2013, Novartis AG (Novartis) announced results of a Phase III
trial of the investigational compound LBH589 (panobinostat) in combination
with bortezomib and dexamethasone. According to the Company, the study met the
primary endpoint of significantly extending progression-free survival in
patients with relapsed or relapsed and refractory multiple myeloma when
compared to bortezomib plus dexamethasone alone. Novartis informed that LBH589
showed significant clinical benefit bringing it a step closer to becoming the
first in its class of anticancer agents to be available to patients with
multiple myeloma. "Results from this study show improved outcomes for these
multiple myeloma patients who otherwise have few options to treat this
incurable disease," said Alessandro Riva, Global Head, Oncology Development
and Medical Affairs, Novartis Oncology. "Given its mechanism of action, LBH589
has the potential to be an important treatment option for multiple myeloma."
The Full Research Report on Novartis AG - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/9b6d_NVS

--

BG Medicine, Inc. Research Report

On December 10, 2013, BG Medicine Inc. (BG Medicine) announced that the
Centers for Medicare and Medicaid Services (CMS) have published the final
determination of the 2014 Medicare national limitation amount for the
Company's galectin-3 blood test at the amount of a crosswalked test, whose
2014 national limitation amount is $30.01. The Company stated that the
national limitation amount will replace the galectin-3 blood test's national
limitation amount of $17.80 that was effective in 2013. "We are very pleased
that CMS has finalized the previously announced preliminary determination of
the Medicare reimbursement rate for our galectin-3 test," said Dr. Paul R.
Sohmer, President and CEO of BG Medicine. The Full Research Report on BG
Medicine, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/e181_BGMD

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.

1.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
2.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
3.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.